Participate in Research. CCReW, Apr2025.

Dear

Welcome to the latest research seeking participants, based on our search of the ANZ CTR.

Also, a quick reminder there are just 3 weeks left to enter the Australian Consumer Partnerships in Research 2025 Awards, which close for entries 22 April. If you have participated in research and had a great experience, nominate the team and what they did to make it great, so other researchers can learn from it. If you're a research centre that aims to provide participants with great research experiences, and have the data to show what you are doing is making a difference for participants, then nominate what you do that's special or innovative. Finally, if you are a part of a partnership involving research professionals and health consumers aiming to improve research or the research sector, then nominate that work. Check out our recent Q&A webinar, if you'd like to know more about the Awards.

We are grateful to Bellberry, Save Our Sons Duchenne Foundation and Curtin University's enAble Institute for their financial support of the Awards, as well all the in-kind supporters helping us promote the Awards. If your organisation wants to demonstrate its commitment to the consumer voice in research, please jump on board as a sponsor. We could really use the help.

Please reach out to me at any time you have questions or feedback about this newsletter or our work.

Last month the ANZCTR was out of action when we did our search. So to make sure we didn't miss anything, the following is a list of studies on the ANZCTR as at 31Mar starting between 1 Feb and 31 Mar 2025.

For more details, click on the links to access the specific trial information.

Cancer

A Phase 2 Study of Olutasidenib with Temozolomide As Maintenance Therapy in Pediatric and Young Adult Patients Newly Diagnosed with High-Grade Glioma (HGG), Including Diffuse Intrinsic Pontine Glioma (DIPG), Which Harbor IDH1 Mutations. NSW, QLD, WA.
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies. VIC.
Locally Optimised Contouring With AI Technology for Radiotherapy (for adults planned for primary breast malignancy). NSW.
Phase 1/2 Clinical Trial of S227928, as a Single Agent and in Combination With Venetoclax in Patients With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, or Chronic Myelomonocytic Leukemia (CMML). VIC, NSW.
A Study to Compare BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma. NSW, QLD, SA, VIC, WA.
A Study to Evaluate BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors. NSW, QLD.
A Study to Compare BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer. NSW, VIC, QLD, WA.
A Phase 1 Study of ARC101 in Advanced Solid Tumors. SA, VIC. Phase 1b Study of ORIC-114 in Combination with Amivantamab in Patients with EGFR Exon20 Insertion Mutant non-small cell lung carcinoma. VIC.
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors. NSW.
Phase 0/1 Study of 177Lu-RAD202, a Lutetium-177 Radiolabeled Single Domain Antibody Against Human Epidermal Growth Factor Receptor 2 in Patients with Advanced Solid Tumours. WA.
A Clinical Study of V940 and BCG in People With Bladder Cancer. NSW.
Radiation Therapy of the prostate, assessing toxicities and quality of life in patients with intermediate risk prostate cancer. VIC.
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer. VIC.

AutoImmunity, Infections + Vaccines

A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age. NSW, QLD, VIC.
A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults. QLD, VIC.
A Phase 1 Basket Study to Evaluate DR-0201 in Patients With Select Autoimmune Rheumatic Diseases. QLD, VIC.

Urology

A Clinical Study to Evaluate the FloStent in Men with Benign Prostatic Hyperplasia Symptoms. NSW.

Respiratory

3-Dimensional Printing Assisted Masks in Children with Obstructive and Restrictive Airway Disease. WA.
A Phase 3 Study to Assess Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps. WA.

Heart Related

YN001-004 in Patients With Coronary Atherosclerosis in Australia. ACT, QLD.

Musculoskeletal

DREAM: a trial of duloxetine compared to placebo for reducing leg pain in people with chronic sciatica. ACT, NSW, NT, QLD, SA, TAS, WA, VIC.
A Study to Evaluate JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis. NSW.
The effect of a topical curcumin formulation (VAS101) on knee pain in adults with knee osteoarthritis. WA.

Neurological

Maximising Aphasia Treatment and Recovery across Australia through Innovative Group Telerehabilitation in people 3 - 12 months post stroke. VIC.

Dermatology

Phase 2 Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate Atopic Dermatitis. NSW, QLD, VIC, WA.
A Study of BBT001 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis. WA.
A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study of EVO301 in Adults with Atopic Dermatitis. NSW, QLD.

Mental Health

Evaluating the use of digitally enhanced treatment models in early intervention for youth with bipolar disorder. VIC.
The Effects of Insomnia Treatment on Overnight Regulation of Emotional Memories and Risk for Mental Disorders. NSW.

Intensive Care

Full face (Nivairo®) versus a bridge free full face (Visairo®) mask for non-invasive ventilation in intensive care unit. VIC.

Pregnancy/Infant/Paediatric/Adolescent

A Research Study Testing NGM120 in Pregnant Women with Severe Nausea and Vomiting (Hyperemesis Gravidarum). NSW, QLD, SA, VIC.

Obesity

A Phase IIb Study to Evaluate Co-administration of AZD9550 and AZD6234 in Participants Living With Obesity or Overweight With Co-morbidity. QLD, NSW, SA, VIC.
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight. NSW, VIC.
A First-in-human Study of HCR-188 in Overweight or Obese Otherwise Healthy Volunteers Without Type 2 Diabetes. QLD.

Healthy volunteers

Placebo-controlled Study of Single and Multiple Ascending Doses of UDP-003 in Healthy Human Participants and Patients. SA.
A Phase 1, First in Human Study of GB-7624 administered subcutaneously in Healthy Adult participants. QLD.
A Phase I, First in Human Study to Assess NYR-BI03 in Healthy Participants, When Administered as a 3-hour Infusion. NSW.

Other

Omics of saliva, GCF and plaque in periodontitis management. QLD.
An examination into the anti-stress and anti-fatigue effects of an ashwagandha extract (NRAHG001) in stressed adults. WA.
Analogue versus Digital Intervention in Chest Trauma (ADICT), in participants 16 years or older. VIC.
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa. NSW.
A Research Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease. NSW, VIC, WA.
Effect of Maolactin™ FMR on Exercise Recovery, Inflammation and Muscle Comfort in an Otherwise Healthy Population. QLD.

Note we have no connection/involvement with any of the above studies. We source this list manually from multiple sources. Unless otherwise indicated, we have not being paid to list the study, and a study appearing in this list is not an endorsement of the quality, relevance of or consumer involvement in the project. We encourage people to do their due dligence on the suitability of any research study for their specific circumstances.

If you are a sponsor or researcher that wants to let people know about your newly opened study, please complete our request form or contact us (it's free to list a study once).

You have until the 22 April to submit a nomination for one of the six categories of Australian Consumer Partnerships in Research 2025 Awards (#CPIR2025Awards) below:

A. Excellence in Consumer Partnership in Non-Commercial Research

B. Excellence in Consumer Partnership in Industry-Funded Research and Development

C. Excellence in Consumer Partner Capacity Building

D. Excellence in Research Participant Experience

E. Outstanding individual consumer impact on Health and Medical Research

F. Outstanding Consumer Advisory Group Impact on Health and Medical Research

For more information, visit the Awards website, and Awards entry platform, or watch the Q&A webinar recording.